Chitogenx

Chitogenx ROE

The Return on Equity (ROE) of Chitogenx (CHGX.CN) as of Oct 17, 2026 is 25.15 %. In the previous year, Return on Equity (ROE) was 63.29 % — a change of -60.26% (lower).

ROE

25.15 %

YoY

-60.26%

Last updated:

In 2024, Chitogenx's return on equity (ROE) was 25.15 %, a -60.26% increase from the 63.29 % ROE in the previous year.

The Chitogenx ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2021
209.44 CAD
Jan 1, 2022
69.27 CAD
Jan 1, 2023
63.29 CAD
Jan 1, 2024
25.15 CAD
The Chitogenx ROE history
YEARROEYoY
25.15 %-60.26%
63.29 %-8.63%
69.27 %-66.93%
209.44 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Chitogenx Stock analysis

What does Chitogenx do? ChitogenX Inc., based in Kirkland, Quebec, is a clinical-stage biotech company developing therapeutic soft tissue repair technologies for orthopaedic and sports medicine surgeries. The company focuses on a proprietary biopolymer combined with autologous platelet-rich plasma (PRP), designed to enhance healing rates for tendon, ligament, meniscus, and cartilage injuries. The technology is integrated into routine surgical procedures without extending operation times, and the firm explores potential applications beyond soft tissue repair. Chitogenx is one of the most popular companies on Eulerpool.

ROE Details

Decoding Chitogenx's Return on Equity (ROE)

Chitogenx's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Chitogenx's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Chitogenx's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Chitogenx’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Chitogenx stock

Return on Equity (ROE) of Chitogenx is 25.15 % in 2024.

Return on Equity (ROE) of Chitogenx changed from 63.29 % to 25.15 %, representing a -60.26% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Chitogenx since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Chitogenx with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Chitogenx

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Chitogenx